OncLive | Latest Data Further Support Ibrutinib's Efficacy in CLL OncLive Combining ibrutinib with the chemoimmunotherapy regimen of bendamustine (Treanda) plus rituximab (Rituxan) demonstrated a high level of activity and was tolerable for patients with relapsed or refractory CLL.1 Presenting the final results of the 30 ... Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies |
